CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 56 enrolled
Drug / intervention
minocycline hydrochloride +3 moredrug
Likely dose
minocycline hydrochloride 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02203552
NCT02203552Phase 2Completed
CompareCT.gov

Randomized Placebo Controlled Study of Minocycline for Amelioration of Chemotherapy Induced Affective Disorders

Ohio State University Comprehensive Cancer Center·interventional·Posted Jul 30, 2014·Updated Jan 8, 2025

In Brief

A Phase 2 clinical trial evaluating minocycline hydrochloride, placebo, and 2 other interventions for Anxiety Disorder and 8 related conditions. Completed, enrolled 56 participants across 1 site.

Detailed Summary

This randomized clinical trial studies how well minocycline hydrochloride works in reducing chemotherapy induced depression and anxiety in patients with stage I-III breast cancer. Minocycline hydrochloride may prevent changes in memory and thinking and improve the quality of life of breast cancer patients receiving chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety Disorder, Depression, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 30, 2014
Enrollment StartJun 23, 2015
Primary CompletionJun 15, 2020
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 11.9 years ago

Interventions

minocycline hydrochloridedrug

100 mg bid given by mouth for 9 weeks

placeboother

Placebo given by mouth for 9 weeks

laboratory biomarker analysisother

Correlative blood levels for cortisol, high sensitivity c-reactive protein (hs-CRP) and inflammatory factors including but not limited to IL-6, TNF-α, IL-1β, and MCP-1 will also be obtained weekly on protocol.

Questionnaire administrationother

The CES-D and STAI will be administrated weekly.